After uplifting over 64,006 families living under extremely poor conditions in the state by ensuring them uninterrupted ...

Tiragolumab plus Tecentriq did not improve progression-free survival compared to Imfinzi in stage 3 NSCLC post-cCRT. Median progression-free survival and overall survival were similar between the ...

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.

Tiragolumab plus atezolizumab did not improve progression-free survival compared to durvalumab in stage III NSCLC patients post-cCRT. Median progression-free survival and overall survival were similar ...

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...

Get ready for a relaxed weekend gaming session because these free games will make sure you don't get up from that couch.

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

() -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...